Updated:
National PKU Alliance
National PKU Alliance funds PKU research and maintains the patient registry that biotech developers rely on for natural-history data.
National PKU Alliance
Move Your Pheet 2026 registration is now open! Show your support for the PKU community this May. Get involved.
General information
Firm type
Foundation
Year founded
2008
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Washington
Corporate office
1802 Vernon Street NW PMB2389, Washington, DC 20009, United States
Principals
Rhonda Connolly
President
Catherine Warren
Executive Director
Mark E. Gralen
Vice President
Dan Lazzari
Treasurer
Alison Reynolds
Secretary
Elaina Jurecki, M.S., R.D.
Director of Research Development
Kelsey McQueen, M.S., C.G.C.
Associate Director of Research Development
Sector focus
Frequently asked questions
Who directs the NPKUA's research funding decisions?
Elaina Jurecki serves as Director of Research Development, supported by Associate Director Kelsey McQueen. The organization's Scientific Advisory Board, established in 2009, reviews and approves grant proposals. Jurecki brings 15 years of industry experience from BioMarin Pharmaceutical and 20 years as a regional metabolic coordinator for Kaiser Northern California.
How does the NPKUA source its research funding?
The primary funding source is the Lifting the Limits for PKU fundraising gala series, launched in 2015. The organization also accepts direct individual and corporate donations. Audited financial statements published on the NPKUA website detail annual revenue and program spending.
What is the PKU Patient Registry and why does it matter to drug developers?
Launched in 2017, the Registry aggregates longitudinal health data and patient-reported outcomes from individuals living with PKU. Biopharmaceutical companies use this data to understand disease progression, identify clinical-trial endpoints, and recruit participants. The NPKUA also runs a sponsored genetic testing program to expand the Registry's data layer.
Is the NPKUA a family office or an investment vehicle?
No. The National PKU Alliance is a section 501(c)(3) non-profit patient-advocacy and research-funding organization. It does not manage a pooled investment portfolio or make for-profit investments. All capital flows to research grants, community support programs, and Registry operations.
Which companies in the PKU therapeutic space interact with the NPKUA?
Several board members have held senior roles at BioMarin Pharmaceutical, which markets Kuvan and Palynziq for PKU. The Alliance consults for biotech organizations developing metabolic-genetic treatments, though it does not publicly list specific corporate partners. Its Scientific Advisory Board and Registry serve as common touchpoints for drug developers.
Does the NPKUA fund early-stage academic research or only clinical-stage programs?
The Alliance funds early-stage translational research. Its first grant in 2010 supported Denise Ney's work on GMP usage in medical foods. Subsequent grants have targeted preclinical and clinical projects through an open, SAB-reviewed process.
How does the NPKUA's governance separate fundraising from research grant-making?
A board of directors with legal, financial, and rare-disease drug-development expertise provides fiduciary oversight. Day-to-day development and fundraising are managed by Susie Gray, while research development is managed independently by Elaina Jurecki. The Scientific Advisory Board provides an additional, external review layer for grants.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: